We have evaluated the effect of neonatal administration of mouse prolactin (PRL) antiserum on the developmental expression of T. and B-lymphocytes in the thymus and spleen of female BALB/c mice. Newborn female mice were injected subcutaneously with a 50-,4l aliquot of PRL antiserum or normal rabbit serum on days 1, 2, and 3. On neonatal day 5, the PRL antiserum-treated group had a significantly (P < 0.05) increased population of cells in the thymus and the spleen that were positive for Thy-1.2 and for L3T4. Increases in Thy-1.2-and L3T4-positive cells in the thymus were detectable also on days 8 and 14 in mice that received the PRL antiserum and in mice injected with bromocriptine, a dopamine agonist t4at inhibits PRL release from the anterior pituitary. On neonatal days 21, 28, and 32, there were no significant differences in the percentage of cells positive for Thy-1.2, Ly-2 (formerly Lyt-2), or L3T4 antigens in the thymus. However, there were significant increases in the percentage of Thy-1.2-and L3T4-positive spleen cells in the bromocriptine-treated group at all.times monitored and in the PRL antiserum-treated group except on day 14. In addition, the percentage of splenocytes that were positive for IgG was significantly increased in the PRL antiserum-treatment group on days 8-28, although not on neonatal day 32. Of tissues known to contain PRL receptors, neonatal administration of PRL antiserum or bromocriptine resulted in a significant alteration in the wet weight of spleen and liver, with no significant effect in thymus, heart, and kidney. Pituitary implants also resulted in a significant increase in both concanavalin A-and lipopolysaccharide-stimulated thymidine incorporation into murine splenic lymphocytes prepared from 45-day-old female mice. These data extend the role of PRL as an immunomodulator of adult lymphocyte function to a role in the developmental expression of T-and B-lymphocyte populations in the thymus and spleen of mice.
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A host of diverse biological effects has been ascribed to prolactin (PRL) (1) (2) (3) (4) . An area of interest in terms of the pervasive action of PRL is its effect on humoral and cellmediated immune responses. PRL receptors have been identified on human T and B lymphocytes (5, 6) , and occupation of these receptors by a lactogenic hormone results in the induction of a consistent marker of increased macromolecular synthesis, omnithine decarboxylase (6) (7) (8) . Cyclosporine, the drug of choice used to produce immunosuppression in organ-transplant patients, interferes with binding of PRL to high-affinity receptors on human T and B lymphocytes (6, 9) . In fact, PRL binding to human lymphocytes is totally blocked by the concentration of cyclosporine used in the management of rejection episodes in human heart-transplant patients (10). An elevation in the level of plasma PRL precedes a rejection episode in patients with heart transplants (11) , further implicating PRL in the allograft rejection process.
Recent evidence supports a role for PRL in the mitogenesis of T lymphocytes. At suboptimal concentrations of Con A, the addition of rat PRL to murine splenocytes resulted in a dose-dependent increase in mitogenesis (12) . Further experiments demonstrated that Con A-stimulated splenocytes make and secrete a PRL-like molecule essential for lymphocyte proliferation (13 NaCI], or the vehicle control. Serum was stored frozen until used. On the day of birth, members of some litters received subcutaneous implants of an anterior pituitary or an equalsized piece of muscle from the biceps femoris (as control) from 3-and 5-mo-old female BALB/c donors. The dorsal incisions were sutured with 6-0 silk and sealed with 4% (wt/ vol) Parlodion (Mallinckrodt) dissolved in amyl acetate (Allied Chemical, New York) before the warmed pups were returned to their mothers. Litters were randomly assigned to treatment groups, and litter size was adjusted to about five per litter with the addition or deletion of male pups.
Preparation of Splenocytes and Thymocytes. Mice were sacrificed by cervical dislocation, the chest and abdomen were flooded with 70% ethanol, and spleen and thymus were removed aseptically and placed individually in Hanks' balanced salt solution (HBSS). Cell suspensions were prepared and counted as described (17 (19) , these data support selective increases in singly labeled L3T4+ cells. In the spleen, the percentage of cells immunostained by all of the mAbs was well below the adult levels, particularly in the case of the T-cell markers. These findings are in line with the known immaturity of the immune responsiveness of the spleen, including its inability to produce interleukin 2 (15, 16, 20) .
Persistence of Splenic Alterations in mAb Expression to Maturity. Significant increases in the percentage of L3T4-positive cells were detectable in the PRL antiserum-treated group and in the bromocriptine-treated group at essentially all time points assayed ( Table 2 ). In addition, the percentage of cells positive for the B-cell marker, IgG, was significantly decreased in both the PRL antiserum-treated group and in the group that received bromocriptine. There was no significant difference in the percentage of Ly-2-positive cells at any time monitored. In general, the increase in the percentage of Thy-1.2-positive cells corresponded to the increase in L3T4-positive cells in both the PRL-and the bromocriptine-treated groups. The mean fluorescence for IgG and L3T4 detection in the spleen was always higher in the NRS-treated group than in the anti-PRL-treated mice (P < 0.05).
Alteration of Thymic T-Celi Markers by PRL Manipulation Only During Neonatal Weeks 1 and 2. The percentage of L3T4-positive cells was increased in the thymus at neonatal days 5 (Table 1) , 8, and 14 (Table 2) . Again, these increases corresponded to a significant increase in the percentage of Thy-1.2-positive cells, with no detectable difference in the Ly-2-positive cell population.
Effect of Neonatally Administered Anti-mouse PRL or Bromocriptine on the Wet Weight of Organs Known to Possess PRL Receptors. The administration of PRL antiserum on neonatal days 1, 2, and 3 resulted in a significant increase in the net weight of the spleen and the liver on neonatal day 32 (P < 0.05). Thymus, heart, and kidney-other organs also known to contain PRL receptors (7, 21)-did not differ in wet weight from the organs in NRS-treated controls (Table 3 ). In addition, in the bromocriptine-treated group, the spleen weight was significantly increased compared with that of the controls, whereas the liver wet weight was significantly lower than that in the vehicle-treated controls (P < 0.05).
Enhancement (12) .
DISCUSSION
Immune responses now known to involve prolactin action include contact sensitivity skin reaction to dinitrochlorobenzene (22, 23) , antibody formation to sheep erythrocytes and to bacterial LPS (22, 23) , adjuvant arthritis (23) (24) (25) , experimental allergic encephalitis (23), graft-versus-host reaction (26, 27) , allograft rejection process (11, 12, 26) , lymphocyte mitogenesis (11, 12, 27, 28) , natural killer cell activity (29) , cyclosporine immunosuppressive action (5, 6, 27, 30) , and macrophage activation (31, 32) . The earliest endocrine (33) . One of the consistent effects ofTCDD toxicity is a suppression ofboth cell-mediated and humoral immunity, again effects that could now be attributed to the effect of TCDD on PRL levels and PRL receptor activity. Recently, the rapid effect ofTCDD on PRL levels in the serum has been traced to the ability of TCDD to increase the steady-state level of dopamine in the median eminence (34) .
Thus, the data presented in this paper extend the role of PRL as an immunomodulator ofadult lymphocyte function to include participation in the developmental expression of Tand B-lymphocyte populations in the thymus and spleen of mice. Whether these developmental differences result in altered immune responses remains to be determined. The effect oflong-term increase ofPRL level demonstrated herein coincides with the effect of PRL on Con A-stimulated mitogenesis in vitro (12) , further supporting the physiological relevance of these findings. The extensive evidence of PRL action on the mammalian immune system mandates further studies of its alterations in known immunodeficient states.
